Viamet Pharmaceuticals, Inc. - Product Pipeline Review - 2016

  • ID: 3734737
  • Company Profile
  • 33 pages
  • Global Markets Direct
1 of 4
Viamet Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

‘Viamet Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Viamet Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Viamet Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Viamet Pharmaceuticals, Inc.
- The report provides overview of Viamet Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Viamet Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Viamet Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Viamet Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Viamet Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Viamet Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Viamet Pharmaceuticals, Inc. Snapshot

Viamet Pharmaceuticals, Inc. Overview

Key Information

Key Facts

Viamet Pharmaceuticals, Inc. - Research and Development Overview

Key Therapeutic Areas

Viamet Pharmaceuticals, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Viamet Pharmaceuticals, Inc. - Pipeline Products Glance

Viamet Pharmaceuticals, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Viamet Pharmaceuticals, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Viamet Pharmaceuticals, Inc. - Drug Profiles

VT-1161

Product Description

Mechanism of Action

R&D Progress

VT-1129

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Oncology

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Orphan Diseases

Product Description

Mechanism of Action

R&D Progress

VT-1598

Product Description

Mechanism of Action

R&D Progress

VT-1607

Product Description

Mechanism of Action

R&D Progress

VT-1654

Product Description

Mechanism of Action

R&D Progress

VT-1658

Product Description

Mechanism of Action

R&D Progress

VT-1669

Product Description

Mechanism of Action

R&D Progress

VT-1681

Product Description

Mechanism of Action

R&D Progress

Viamet Pharmaceuticals, Inc. - Pipeline Analysis

Viamet Pharmaceuticals, Inc. - Pipeline Products by Target

Viamet Pharmaceuticals, Inc. - Pipeline Products by Route of Administration

Viamet Pharmaceuticals, Inc. - Pipeline Products by Molecule Type

Viamet Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action

Viamet Pharmaceuticals, Inc. - Recent Pipeline Updates

Viamet Pharmaceuticals, Inc. - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Viamet Pharmaceuticals, Inc., Key Information

Viamet Pharmaceuticals, Inc., Key Facts

Viamet Pharmaceuticals, Inc. - Pipeline by Indication, 2016

Viamet Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016

Viamet Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016

Viamet Pharmaceuticals, Inc. - Phase II, 2016

Viamet Pharmaceuticals, Inc. - Phase I, 2016

Viamet Pharmaceuticals, Inc. - Preclinical, 2016

Viamet Pharmaceuticals, Inc. - Pipeline by Target, 2016

Viamet Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016

Viamet Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016

Viamet Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016

Viamet Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016

List of Figures

Viamet Pharmaceuticals, Inc. - Pipeline by Indication, 2016

Viamet Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016

Viamet Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016

Viamet Pharmaceuticals, Inc. - Pipeline by Target, 2016

Viamet Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016

Viamet Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016

Viamet Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll